HSE has approved Spinraza for spinal muscular atrophy after lengthy campaign

It's good news for those suffering from the rare muscle-wasting disease spinal muscular atrophy (SMA). 

The HSE has approved Spinraza, the only treatment on the market for the disease.

It has been decided that the drug will be reimbursed, after a drugs group voted by a narrow majority in May against it. 

This decision has been celebrated by Minister for Health Simon Harris.

He took to Twitter to write, ''Welcome news today that Spinraza is now approved by the HSE. This is the first ever treatment for children with SMA.''

He continued, ''I know how hard the long journey to get here has been for families but very glad children in Ireland will now have access.''

The HSE had previously said the drug would cost about €600,000 in the first year to treat each of the 25 Irish children with the disease and €380,000 a year after. 

Spinraza is approved in 26 countries around Europe.




Hello Mama!
Help us help you by allowing us and our partners to remember your device as having browsed MummyPages and serve you better content and ads

We're on a mission to help our mums and their families thrive by informing, connecting and entertaining.

Join us in our mission by consenting to the use of cookies and IP address recognition by us and our partners to serve you content (including ads) best suited to your interests, both here and around the web.

We promise never to share any other information that may be deemed personal unless you explicitly tell us it's ok.

If you want more info, see our privacy policy.